Intracerebral Hemorrhage
TICH-2
In adult patients with acute spontaneous intracerebral hemorrhage treated within 8 hours of onset, does tranexamic acid, compared with placebo, improve functional outcome (mRS score) at 90 days?
SWITCH
In adult patients (≥18 years) with spontaneous supratentorial intracerebral hemorrhage (volume 10-60 mL, GCS 5-12, pre-ICH mRS 0-1), does early surgical hematoma evacuation (within 24 hours) plus medical care, compared with initial conservative medical care alone, improve functional outcome (mRS score) at 180 days?
STOP-AUST
In adult patients with acute spontaneous intracerebral hemorrhage and a CT angiography spot sign, treated within 4.5 hours of onset, does tranexamic acid, compared with placebo, reduce hematoma expansion at 24 hours?
STICH-II
In adult patients with spontaneous superficial lobar intracerebral hemorrhage (10-100 mL, GCS ≥6T/7), does a policy of early surgical hematoma evacuation by craniotomy plus best medical treatment, compared with best medical treatment alone (with delayed surgery if needed), improve outcome at 6 months?
STICH
In adult patients with spontaneous supratentorial intracerebral hemorrhage, does a policy of early surgical hematoma evacuation plus best medical treatment, compared with best medical treatment alone (with delayed surgery if needed), improve outcome at 6 months?
PATCH
In adult patients (GCS ≥8) with spontaneous supratentorial intracerebral hemorrhage who were on antiplatelet therapy and presented within 6 hours, does platelet transfusion plus standard care, compared with standard care alone, reduce death or dependence at 3 months?
MISTIE III
In adult patients (18-80 years) with spontaneous supratentorial intracerebral hemorrhage (volume ≥30 mL, GCS 4-14), does minimally invasive catheter evacuation followed by alteplase instillation, compared with standard medical care alone, improve functional outcome (mRS 0-3) at 365 days?
INTREPID
In critically ill adult patients with acute vascular brain injury (ischemic stroke, ICH, or SAH), does active fever prevention targeting 37.0°C using an automated surface device, compared with standard reactive fever treatment, improve functional outcome at 3 months?
INTERACT2
In patients with acute intracerebral hemorrhage does intensive blood pressure control (target systolic BP <140 mmHg) improving functional outcome at 90 days as compared with standard care (target systolic BP <180 mmHg)?
INCH
In adult patients with VKA-associated intracerebral hemorrhage (INR ≥2.0, symptoms <12h), does prothrombin complex concentrate (PCC) compared with fresh frozen plasma (FFP), both with vitamin K, lead to more rapid and effective INR normalization and affect hematoma expansion and clinical outcomes?
i-DEF
In adult patients (18-80 years) with primary spontaneous supratentorial intracerebral hemorrhage, does deferoxamine mesylate (32 mg/kg/day for 3 days) initiated within 24 hours, compared with placebo, show sufficient promise of improving functional outcome (mRS 0-2) at 90 days to warrant a phase 3 trial (i.e., not futile)?
FAST
In adult patients with acute intracerebral hemorrhage treated within 4 hours of onset, does recombinant activated factor VII (rFVIIa) at doses of 20 μg/kg or 80 μg/kg, compared with placebo, reduce death or severe disability at 90 days?
ENRICH
In adult patients (18-80 years) with spontaneous supratentorial intracerebral hemorrhage (lobar or basal ganglia, volume 30-80 mL, GCS 5-14), does early minimally invasive parafascicular surgery (MIPS) plus medical management, compared with medical management alone, improve functional outcome (utility-weighted mRS) at 180 days?
CLEAR III
In adult patients (18-75 years) with spontaneous supratentorial ICH (<30 mL) and obstructive IVH requiring an EVD, does intraventricular administration of alteplase via the EVD, compared with EVD management with or without saline irrigation, improve functional outcome at 180 days?
ATACH-2
In patients with acute intracerebral hemorrhage and SBP ≥180 mmHg, does intensive blood pressure control (target SBP 110-139 mmHg) reduce death or disability at 3 months compared with standard care (target SBP 140-179 mmHg)?
ANNEXA-I
In adult patients with acute major bleeding (including ICH) associated with recent use of a factor Xa inhibitor, does andexanet alfa, compared with usual care, result in better hemostatic efficacy and improved clinical outcomes?